^
Association details:
| Biomarker: | EGFR T790M |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial
Published date:
01/07/2021
Excerpt:
...osimertinib plus bevacizumab vs osimertinib alone, the combination arm failed to show prolongation of PFS in patients with advanced lung adenocarcinoma with EGFR T790M mutation….median PFS was not longer with osimertinib plus bevacizumab (9.4 months vs 13.5 months; adjusted hazard ratio, 1.44; 80% CI, 1.00 to 2.08; P = .20)...
DOI:
10.1001/jamaoncol.2020.6758
